Natera, Inc. (NTRA) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 40
- Profitability 70
- Business Quality 65
- Balance Sheet 45
- Cash Flow 80
Why this rating?
Health 45/100 — Speculative
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Natera, Inc. (NTRA) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Natera, Inc. 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Stretched
Financial highlights
Valuation
- Forward P/E -3,633.86
- EV/Revenue 17.16
Profitability
- Revenue Growth 37.7%
- Gross Margin 65.2%
- Operating Margin -10.3%
- Net Margin -7.1%
- ROE -12.5%
Financial strength
- Cash $1.09B
- Debt $238.49M
- Net Cash $853.01M
- Free Cash Flow $76.11M
- Current Ratio 3
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$42.45 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Illumina, Inc. Diagnostics & Research ILMN$211.06 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$50.31 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$42.38 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$205.23 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$235.50 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Sotera Health Company Diagnostics & Research SHC$18.59 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$127.08 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Natera, Inc. (NTRA).